PRODUCT PIPELINE


HOME > PRODUCT PIPELINE > M802—HER2×CD3
M802—HER2×CD3

Name: Injectable humanized recombinant anti-HER2 and anti-CD3 bispecific antibody

Intro: Using in house IP protected YBODY® format, first bispecific antibody under CDE review in China, clinical studies planned to initiate in 2017, target patient population includes breast and gastric cancer

Advantages: Extensive preclinical studies have demonstrated high potency, manageable toxicities, long half life, less immunogenecity, robust manufacturing process and high stability

Structural Features and Advantages
Humanized: Low immunogenicity


Full length IgG with Fc: Longer half life

Asymmetric structure: solved mis-pairing problem and process development issues

Tri-functional MOA:high potency with low dose

Cytotoxicity towards HER2 medium and low expression